leadf
logo-loader
viewPfizer

Pfizer coronavirus vaccine passes early stage trials

Regulatory review for the candidate is sought as early as October

Pfizer - Pfizer coronavirus vaccine passes early stage trials

Pfizer Inc (NYSE:PFE) said the COVID-19 vaccine developed in conjunction with BioNTech SE (NASDAQ:BNTX) has passed early stage trials.

The cohort was made of 45 healthy adults aged 18-55 who received two doses of 10 micrograms, 30 micrograms, or 100 micrograms of the mRNA jab, or a placebo.

READ: Pfizer and BioNTech land US$1.95bn COVID-19 vaccine order from US Government

The strongest immune response was in the 30 micrograms dose, while there was no notable difference in efficacy between that and the 100 micrograms, though the latter caused more side effects.

Last month, the US giant said the candidate was on track to start a planned Phase 2b/3 safety and efficacy trial, with regulatory review sought as early as October.

The pair are targeting global manufacturing of the first 100mln doses by the end of 2020 and another 1.3bn doses in 2021.

Americans will be immunised for free consistent with US government’s commitment for free access for COVID-19 vaccines.

The UK previously ordered 30mln doses.

Quick facts: Pfizer

Price: 36.63 USD

NYSE:PFE
Market: NYSE
Market Cap: $203.55 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Luminex Resources CEO says stay tuned for drill results out of its Condor...

Luminex Resources Corp. (TSXV: LR) (OTCQX: LUMIF) CEO Marshall Koval tells Proactive the Vancouver-based mining company is making progress on its Condor Gold-Copper Project in Zamora-Chinchipe Province, southeast Ecuador. Koval says the group has advanced metallurgy at the site, continuing to...

2 days, 7 hours ago

2 min read